events
05 July 2022
Jean De Gunzburg speaker at the 8th Annual Microbiome Connect Europe 2022 on July 6 at 11.30am CET
Jean De Gunzburg will attend the 8th Annual Microbiome Connect: Europe 2022 on July 6-7 2022 and participate as a…
Our vision
A HEALTHY MICROBIOME FOR CANCER PATIENTS
Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome and oncology fields.
Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiome to prevent and cure life-threatening diseases.
We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.
Our most advanced product
DAV132
DAV132 is a unique and first-in-class oral gut microbiome protector, co-administered with antibiotics and chemotherapy, to maintain patients’ microbiome health during these critical treatments. Its development is supported by robust data from 7 clinical studies with a demonstrated safety, mode of action and biological efficacy in 500 patients and human volunteers.
DAV132 is the world most advanced product protecting against the medical consequences of intestinal microbiome dysbiosis in cancer patients.
